Current state of liposome-complexed drugs in the treatment of cancer patients.
de Vries
E G
EG
Mulder
N H
NH
Daemen
T
T
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy*; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D010714:Phosphatidylethanolamines; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine